Obinutuzumab containing conditioning regimen for CLL patients and patients with Richter`s transformation requiring an allogeneic stem cell transplantation
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Jan 2019
At a glance
- Drugs Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms CLLTX1
- 05 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 02 Jun 2017 Status changed from not yet recruiting to recruiting.
- 04 Apr 2017 New trial record